Profile

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY797. Vitrakvi® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China.

Please click here to see important safety information for BRAFTOVI + MEKTOVI.

Stock Quote & Chart

Copyright West LLC. Minimum 15 minutes delayed.

Transfer Agent

6201 15th Avenue
Brooklyn, NY 11219
Phone: (800) 937-5449
Fax: (718) 236-4588
E-mail: Info@amstock.com
Website: http://www.amstock.com

Legal

Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
1440 New York Avenue, N.W.
Washington, D.C.  20005
Phone: (202) 371-7000

Accountants

KPMG LLP
707 Seventeenth Street, Suite 2700
Denver, CO 80202
Phone: (303) 295-5572

Shareholder Tools